Positive News SentimentPositive NewsNASDAQ:NRXP NRx Pharmaceuticals (NRXP) Stock Price, News & Analysis $2.41 +0.07 (+2.99%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$2.38▼$2.5050-Day Range$2.15▼$4.0652-Week Range$1.90▼$7.33Volume13,927 shsAverage Volume58,541 shsMarket Capitalization$25.79 millionP/E RatioN/ADividend YieldN/APrice Target$43.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get NRx Pharmaceuticals alerts: Email Address NRx Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,684.2% Upside$43.00 Price TargetShort InterestHealthy4.21% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.45 out of 5 starsMedical Sector541st out of 936 stocksPharmaceutical Preparations Industry245th out of 436 stocks 3.5 Analyst's Opinion Consensus RatingNRx Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageNRx Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about NRx Pharmaceuticals' stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted4.21% of the float of NRx Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverNRx Pharmaceuticals has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in NRx Pharmaceuticals has recently decreased by 2.15%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldNRx Pharmaceuticals does not currently pay a dividend.Dividend GrowthNRx Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NRXP. Previous Next 2.7 News and Social Media Coverage News SentimentNRx Pharmaceuticals has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for NRx Pharmaceuticals this week, compared to 2 articles on an average week. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, NRx Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders21.06% of the stock of NRx Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 4.27% of the stock of NRx Pharmaceuticals is held by institutions.Read more about NRx Pharmaceuticals' insider trading history. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of NRx Pharmaceuticals is -0.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of NRx Pharmaceuticals is -0.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about NRx Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad True Market InsidersThe #1 Crypto for 2024 (3 Cent Coin)Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 different coins that have returned over 100%... Today, he is now making the biggest crypto call of his ENTIRE career…Click For My #1 FREE Crypto for 2024 About NRx Pharmaceuticals Stock (NASDAQ:NRXP)NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned FDA-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.Read More NRXP Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NRXP Stock News HeadlinesJuly 1, 2024 | prnewswire.comNRx Pharmaceuticals (NASDAQ:NRXP) Publishes Shareholder Update LetterJune 28, 2024 | prnewswire.comNRx Pharmaceuticals (NASDAQ:NRXP) to Proceed with Two New Drug Applications in 2024; NRX-101 has Been Returned to the Company for FilingJuly 27, 2024 | Darwin (Ad)Top Stock Unveiled!Ready to discover the standout stock of 2024? We’ve identified a single buy & hold gem that’s poised to redefine your portfolio. Download our exclusive report now and dive into the Insights. Click below to opt-in and receive up to two additional free bonus subscriptions. Unsubscribe at any time.June 20, 2024 | prnewswire.comNRx Pharmaceuticals, Inc. (Nasdaq:NRXP) to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference on June 27, 2024June 18, 2024 | prnewswire.comNRx Pharmaceuticals (NASDAQ:NRXP) Appoints Neuroscience, Information Technology and Medical Technology Veteran to its Board of DirectorsJune 10, 2024 | prnewswire.comNRx Pharmaceuticals (NASDAQ:NRXP) Publishes Shareholder Update LetterMay 28, 2024 | prnewswire.comNRx Pharmaceuticals (Nasdaq:NRXP) Presents Landmark Trial of NRX-101 in Suicidal Bipolar Depression At the American Society of Clinical Psychopharmacology Annual Meeting: NRX-101 is the First Oral Antidepressant Demonstrated to Reduce Suicidality in Bipolar DepressionMay 19, 2024 | msn.comNRx Pharmaceuticals Holds Promise for Investors and Patients AlikeJuly 27, 2024 | Darwin (Ad)Top Stock Unveiled!Ready to discover the standout stock of 2024? We’ve identified a single buy & hold gem that’s poised to redefine your portfolio. Download our exclusive report now and dive into the Insights. Click below to opt-in and receive up to two additional free bonus subscriptions. Unsubscribe at any time.May 15, 2024 | msn.comNRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Q1 2024 Earnings Call TranscriptMay 15, 2024 | finanznachrichten.deNRx Pharmaceuticals, Inc.: NRx Pharmaceuticals (Nasdaq:NRXP) Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 15, 2024 | finance.yahoo.comNRX Pharmaceuticals Inc (NRXP) (Q1 2024) Earnings Call Transcript Highlights: Strategic ...May 14, 2024 | investorplace.comNRXP Stock Earnings: NRX Pharmaceuticals Misses EPS for Q1 2024May 14, 2024 | prnewswire.comNRx Pharmaceuticals (Nasdaq:NRXP) Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 13, 2024 | msn.comNRx Pharmaceuticals to Unveil First Quarter Financial Results and Corporate UpdateMay 13, 2024 | msn.comNRx Pharmaceuticals Makes Significant Stride with New Depression Drug, Aims for Accelerated FDA ApprovalMay 8, 2024 | markets.businessinsider.comNRx Pharmaceuticals Eyes First Commercial Revenue in 2024, Announces Breakthroughs in Bi-Annual Milestone UpdateMay 8, 2024 | prnewswire.comNRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Participate in the EF Hutton Annual Global Conference on May 15, 2024See More Headlines Receive NRXP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NRx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/14/2024Today7/26/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:NRXP CUSIPN/A CIK1719406 Webwww.bigrockpartners.com Phone(484) 254-6134FaxN/AEmployees2Year FoundedN/APrice Target and Rating Average Stock Price Target$43.00 High Stock Price Target$43.00 Low Stock Price Target$43.00 Potential Upside/Downside+1,684.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($3.14) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-30,150,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-260.31% Debt Debt-to-Equity RatioN/A Current Ratio0.18 Quick Ratio0.18 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($1.38) per share Price / Book-1.75Miscellaneous Outstanding Shares10,701,000Free Float8,447,000Market Cap$25.79 million OptionableOptionable Beta1.26 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesDr. Jonathan C. Javitt M.D. (Age 67)M.P.H., Co-Founder, Chief Scientist Officer & Chairman Comp: $873.7kMr. Stephen H. Willard Esq. (Age 63)Acting Corporate Secretary, CEO & Director Comp: $501.19kDr. Riccardo Panicucci Ph.D. (Age 62)Chief Technology Officer Comp: $240kDr. Seth L. Van Voorhees Ph.D. (Age 63)Treasurer Comp: $399.96kMr. Richard Clavano Narido (Age 46)Interim CFO, Principal Financial Officer & Principal Accounting Officer Suzanne MessereInvestor RelationsDr. Philip T. Lavin Ph.D. (Age 77)Chief Methodologist Dr. Dennis K. McBride Ph.D.Chief Strategy Officer & Senior ScientistMr. Matthew Patrick Duffy (Age 61)Chief Business Officer More ExecutivesKey CompetitorsHall of Fame Resort & EntertainmentNASDAQ:HOFVAclaris TherapeuticsNASDAQ:ACRSSagimet BiosciencesNASDAQ:SGMTDBV TechnologiesNASDAQ:DBVTAtlantic Coastal Acquisition Corp. IINASDAQ:ACABView All CompetitorsInsidersAaron GorovitzBought 3,500 shares on 8/30/2023Total: $11,200.00 ($3.20/share)Jonathan C JavittBought 20,000 shares on 8/22/2023Total: $64,000.00 ($3.20/share)View All Insider Transactions NRXP Stock Analysis - Frequently Asked Questions How have NRXP shares performed this year? NRx Pharmaceuticals' stock was trading at $46.00 on January 1st, 2024. Since then, NRXP stock has decreased by 94.8% and is now trading at $2.41. View the best growth stocks for 2024 here. How were NRx Pharmaceuticals' earnings last quarter? NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) posted its earnings results on Tuesday, May, 14th. The company reported ($0.74) earnings per share for the quarter. When did NRx Pharmaceuticals' stock split? NRx Pharmaceuticals shares reverse split before market open on Tuesday, April 2nd 2024. The 1-10 reverse split was announced on Tuesday, April 2nd 2024. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, April 2nd 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. How do I buy shares of NRx Pharmaceuticals? Shares of NRXP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:NRXP) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredJ.P. Morgan’s DIRE WarningWhen the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal war...Behind the Markets | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NRx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NRx Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free nrxp Stock Alerts